The nurse is reviewing the medication orders for a patient who will be receiving aminoglycoside therapy.
Which other medication or medication class, if ordered, would be a potential interaction concern?

Choice A rationale:

Waiting to see if the fever gets worse is not the best course of action. Fever is a symptom that the body is fighting off an infection, and it can cause discomfort in children. However, the main concern with chickenpox and fever is not the fever itself, but the risk of complications from the chickenpox. Therefore, it’s important to manage the fever for the child’s comfort but also monitor for any signs of complications.

Choice B rationale:

Aspirin should not be given to children or teenagers who have chickenpox or flu symptoms before a doctor is consulted about Reye’s Syndrome, a rare but serious illness. Reye’s syndrome is a potentially life-threatening condition that has been associated with aspirin use in children and adolescents with viral illnesses, especially chickenpox or influenza.

Choice C rationale:

Acetaminophen (Tylenol) should be used to reduce his fever, not aspirin. This is because of the risk of Reye’s syndrome associated with aspirin use in children and adolescents who have viral illnesses. Acetaminophen is a safe and effective choice for fever reduction in children.

Choice D rationale:

While it’s important to always follow the instructions on the bottle when giving medication, aspirin should not be used in children or teenagers with chickenpox due to the risk of Reye’s syndrome. Therefore, this advice could potentially lead to a dangerous situation.

Choice A rationale:

Zidovudine, also known as AZT, is a medication used for the treatment of human immunodeficiency virus (HIV) infection. One of the major dose-limiting toxic effects of Zidovudine is hematologic toxicity, which manifests clinically as anemia, neutropenia, and sometimes as platelet deficits with onset after several weeks of treatment. This hematologic toxicity is essentially a form of bone marrow suppression. Therefore, bone marrow suppression is the dose-limiting adverse effect of zidovudine therapy.

Choice B rationale:

Retinitis is not a known dose-limiting adverse effect of zidovudine. While zidovudine has a range of side effects, retinitis is not commonly associated with its use.

Choice C rationale:

Renal toxicity is not a known dose-limiting adverse effect of zidovudine. While zidovudine can have various side effects, renal toxicity is not typically one of them.

Choice D rationale:

Hepatotoxicity is not the dose-limiting adverse effect of zidovudine. While severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of zidovudine, it is not considered the dose-limiting adverse effect. The dose-limiting adverse effect is more specifically related to hematologic toxicity, which includes bone marrow suppression.